No Abstract BioWorld International CorrespondentMovetis NV is testing the mettle of European life sciences investors with the sector's first sizeable initial public offering since the first quarter of 2008.With a European product launch imminent, the company offers a far less risky proposition than most, however. Read More
LONDON - The flood of new money into European biotechs continued as Oxagen Ltd. announced the completion of a £16 million (US$26.4 million) third-round funding, with new investor Novartis Venture Funds leading the round. (BioWorld International) Read More
